DiaphOne Therapeutics
DiaphOne Therapeutics was created by NLC Health Ventures from technology originating in NYU Langone Health. The company is led by an excellent team of scientists and entrepreneurs with 30+ years of R&D and business experience.
Treating diabetic nephropathy and other diabetic complications, with potential for additional indications like ALS, Alzheimer’s Disease and breast cancer.
DiaphOne Therapeutics is developing first in class small molecules to treat diabetic nephropathy and other diabetic complications, with potential for additional indications like ALS, Alzheimer’s Disease and breast cancer.
Currently, there are no curative treatments for diabetic nephropathy or other diabetic complications. The approved marketed medications only address secondary disease pathways and not the diseased organ. DiaphOne’s small molecules specifically target the pathophysiology of diabetic complications at their root, without affecting peripheral mechanisms.
Advancing First-in-Class Small Molecule Inhibitors for Targeting the Intracellular RAGE-Diaph1 Interface with Superior Efficacy
DiaphOne develops first in class small molecule inhibitors targeting the intracellular RAGE-Diaph1 interface. The drug candidates have a profile of increased efficacy, decreased redundancy compared to extracellular ligand blocking and have undergone extensive target validation studies.
Raising exploratory Seed capital
Currently raising exploratory Seed capital to complete in vivo PoC and lead optimization studies of the final candidate.
